These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 12853564

  • 1. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE.
    Proc Natl Acad Sci U S A; 2003 Jul 22; 100(15):8933-8. PubMed ID: 12853564
    [Abstract] [Full Text] [Related]

  • 2. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015 Jul 22; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
    Cytometry; 2001 Aug 01; 44(4):338-48. PubMed ID: 11500850
    [Abstract] [Full Text] [Related]

  • 4. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, Gregg JP, Cardiff RD, Borowsky AD, Sweeney C, Carraway KL.
    Cancer Res; 2006 Dec 01; 66(23):11279-86. PubMed ID: 17145873
    [Abstract] [Full Text] [Related]

  • 5. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N, Pust S, Sandvig K.
    Biochim Biophys Acta; 2014 Sep 01; 1843(9):1987-96. PubMed ID: 24747692
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells.
    Neve RM, Sutterlüty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE.
    Oncogene; 2000 Mar 23; 19(13):1647-56. PubMed ID: 10763821
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD, Kao MC, Lin JK.
    J Biol Chem; 2004 Feb 06; 279(6):4479-89. PubMed ID: 14602723
    [Abstract] [Full Text] [Related]

  • 11. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H, Akita RW, Sliwkowski MX, Maihle NJ.
    Cancer Res; 2001 Jun 01; 61(11):4467-73. PubMed ID: 11389077
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.
    Breast Cancer Res; 2013 Jun 01; 15(5):R101. PubMed ID: 24168763
    [Abstract] [Full Text] [Related]

  • 13. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD.
    Mol Cancer Res; 2009 Nov 01; 7(11):1882-92. PubMed ID: 19861407
    [Abstract] [Full Text] [Related]

  • 14. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
    Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH.
    Oncogene; 1995 May 04; 10(9):1813-21. PubMed ID: 7538656
    [Abstract] [Full Text] [Related]

  • 15. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
    Lund CV, Popkov M, Magnenat L, Barbas CF.
    Mol Cell Biol; 2005 Oct 04; 25(20):9082-91. PubMed ID: 16199884
    [Abstract] [Full Text] [Related]

  • 16. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S, Huang X, Lee CK, Liu B.
    Oncogene; 2010 Jul 22; 29(29):4225-36. PubMed ID: 20498641
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2.
    Kawano S, Ikeda W, Kishimoto M, Ogita H, Takai Y.
    J Biol Chem; 2009 Aug 28; 284(35):23793-805. PubMed ID: 19561085
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.
    Mol Cancer Ther; 2012 Mar 28; 11(3):582-93. PubMed ID: 22248472
    [Abstract] [Full Text] [Related]

  • 20. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A.
    Oncogene; 2003 Sep 11; 22(39):7998-8011. PubMed ID: 12970748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.